Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Should FDA Drug Safety Alerts Go To Professionals First?

Executive Summary

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24

You may also be interested in...

PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes

FDA should explain the why of its important regulatory decisions in consumer-friendly language, according to the Pharmaceutical Research and Manufacturers of America

Sharfstein Heads FDA Transparency Task Force

FDA's formation of an internal "Transparency Task Force" is a savvy approach that allows agency leaders to begin making good now on their pledges to enhance openness while giving them six months to decide whether to release any specific new information

FDA Issues Suicidality Alert On Antiepileptics

A class-wide relabeling is expected, but Pfizer says that Neurontin and Lyrica show no signs of increased events.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts